Preview

User

Not a user? Register with this site Forgot your password?

Meditsinskiy sovet = Medical Council

Advanced search

Experience of satralizumab administration in patients with neuromyelitis optica spectrum disorder in the Russian Federation

https://doi.org/10.21518/ms2026-042

Abstract

Introduction. Effectiveness and safety of satralizumab in the treatment of neuromyelitis optica spectrum disorders (NMOSD) have been demonstrated in randomized clinical trials and continue to be evaluated in the real clinical practice (RCP).

Aim. To analyze the experience of satralizumab administration in Russian patients with NMOSD in the RCP.

Materials and methods. The study was a multicenter retrospective. Analyzed data were taken from outpatient charts/medical records. Baseline clinical and demographic characteristics of patients with results on efficacy and safety of satralizumab treatment were assessed.

Results. Data of 71 patients with ages ranging from 12 to 69 years at the start of satralizumab treatment were analyzed. 100% of patients had NMOSD with antibodies to aquaporin-4. At baseline 18.3% of patients were with highly active NMOSD by exacerbation frequency, 69% had previous relapse preventive treatment, 41% received low-dose glucocorticoids. The annualized relapse rate (ARR) during previous 2 years before treatment was 1.26. The median duration of satralizumab therapy was 15 [12; 24.5] months. 58 (82%) patients were relapse-free and included 9 (16%) persons with highly active NMOSD. The ARR decreased to 0.11 over 2 years of therapy (p < 0.001). In 8 (62%) of 13 patients with relapses first attack developed before 6 months of treatment and in 6 (46.2%) cases – during the “clustered period”, 11 (84.6%) patients did not receive low doses glucocorticoids or they were discontinued before 6 months of satralizumab therapy. Adverse events were reported in 19 (26.8%) patients. The neutropenia was the most common. 27 (84.4%) of 32 patients switched from rituximab to satralizumab were relapse-free with a favorable safety.

Conclusions. The analysis of the experience on the satralizumab administration in the RCP demonstrated efficacy and favorable safety profile in Russian patients with NMOSD with antibodies to aquaporin-4 aged 12 years and older.

About the Authors

V. S. Krasnov
Pavlov First Saint Petersburg State Medical University
Russian Federation

Vladimir S. Krasnov - Cand. Sci. (Med.), Associate Professor, Associate Professor of the Neurology Department, Pavlov First Saint Petersburg State Medical University.

6–8, Lev Tolstoy St., St Petersburg, 197022


M. P. Abramova
Saint-Petersburg City Center for Multiple Sclerosis and Other Autoimmune Diseases, City Clinical Hospital No. 31
Russian Federation

Maria P. Abramova - Neurologist, Saint Petersburg City Center for Multiple Sclerosis and Other Autoimmune Diseases, City Clinical Hospital No. 31.

3, Dynamo Ave., St Petersburg, 197110


M. A. Bakalova
Voronezh Regional Clinical Hospital No. 1
Russian Federation

Marina A. Bakalova - Cand. Sci. (Med.), Neurologist of the Multiple Sclerosis Department of the Outpatient Clinic, Voronezh Regional Clinical Hospital No. 1.

151, Moskovskiy Ave., Voronezh, 394066


A. I. Bezvodinskikh
Pavlov First Saint Petersburg State Medical University
Russian Federation

Alexander I. Bezvodinskikh - Neurologist of the First Neurology Department, Pavlov First Saint Petersburg State Medical University.

6–8, Lev Tolstoy St., St Petersburg, 197022


R. Ts. Bembeeva
Pirogov Russian National Research Medical University; Russian’s Children’s Clinical Hospital branch of the Pirogov Russian National Research Medical University
Russian Federation

Raisa Ts. Bembeeva - Dr. Sci. (Med.), Professor of the Department of Neurology, Neurosurgery and Medical Genetics named after L.O. Badalyan, Institute of Neurosciences and Neurotechnologies, Pirogov Russian National Research Medical University; Pediatric Neurologist, Russian Children’s Clinical Hospital, Pirogov Russian National Research Medical University.

1, Ostrovityanov St., Moscow, 117997; 117, Leninsky Ave., Moscow, 119571


Z. S. Gasanova
Vishnevsky Republican Clinical Hospital
Russian Federation

Zaira S. Gasanova - Head of the Multiple Sclerosis Center, Neurologist of the Outpatient Clinic, Vishnevsky Republican Clinical Hospital.

47, Lyakhov St., Republic of Dagestan, Makhachkala, 367008


E. P. Evdoshenko
Saint-Petersburg City Center for Multiple Sclerosis and Other Autoimmune Diseases, City Clinical Hospital No. 31
Russian Federation

Evgeniy P. Evdoshenko - Cand. Sci. (Med.), Director of the Saint Petersburg City Center for Multiple Sclerosis and Other Autoimmune Diseases, City Clinical Hospital No. 31.

3, Dynamo Ave., St Petersburg, 197110


N. V. Zhukovskaya
Leningrad Regional Clinical Hospital; Saint Petersburg State Pediatric Medical University
Russian Federation

Natalia V. Zhukovskaya - Cand. Sci. (Med.), Нead of the Neurology Department for Stroke Patients, Leningrad Regional Clinical Hospital; Assistant of the Department of Medical Rehabilitation and Sports Medicine, Saint Petersburg State Pediatric Medical University.

45, Bldg. 2, Lunacharsky St., St Petersburg, 194291; 2, Litovskaya St., St Petersburg, 194100


O. V. Zaplakhova
Kuvatov Republican Clinical Hospital
Russian Federation

Oksana V. Zaplakhova - Neurologist, Нead of the Republican Center Multiple Sclerosis, Kuvatov Republican Clinical Hospital.

132, Dostoevsky St., Ufa, Republic of Bashkortostan, 450005


S. P. Ivanova
Lipetsk Regional Clinical Hospital
Russian Federation

Sofya P. Ivanova - Neurologist of the Neurology Department, Lipetsk Regional Clinical Hospital.

6a, Moskovskaya St., Lipetsk, 398042


O. S. Ignateva
Novgorod Regional Clinical Hospital
Russian Federation

Olga S. Ignateva - Neurologist, Novgorod Regional Clinical Hospital.

14, Pavel Levitt St., Velikiy Novgorod, 173008


D. S. Kasatkin
Yaroslavl State Medical University
Russian Federation

Dmitry S. Kasatkin - Dr. Sci. (Med.), Associate Professor, Professor of the Department of Nervous Diseases with Medical Genetics and Neurosurgery, Yaroslavl State Medical University.

5, Revolutsionnaya St., Yaroslavl, 150000


D. S. Korobko
Novosibirsk State Regional Clinical Hospital; Novosibirsk State Medical University
Russian Federation

Denis S. Korobko - Cand. Sci. (Med.), Head of Center, Neurologist of Regional Center for Multiple Sclerosis and Other Autoimmune Diseases of the Nervous System, Novosibirsk State Regional Clinical Hospital; Associate of Neurology Department, Novosibirsk State Medical University.

130, Nemirovich-Danchenko St., Novosibirsk 630087; 52, Krasny Ave., Novosibirsk, 630091


E. V. Krivomlina
Scientific Research Institute – Regional Clinical Hospital No. 1 named after Professor S.V. Ochapovsky
Russian Federation

Elena V. Krivomlina - Neurologist of the Neurological Department, Scientific Research Institute – Regional Clinical Hospital No. 1 named after Professor S.V. Ochapovsky.

167, 1st May St., Krasnodar, 350086


V. E. Kushtynova
Smolensk State Medical University
Russian Federation

Valentina E. Kushtynova - Cand. Sci. (Med.), Assistant Professor of the Neurology and Neurosurgery, Smolensk State Medical University.

28, Krupskaya St., Smolensk, 214019


V. M. Lebedev
Bechtereva Institute of the Human Brain of the Russian Academy of Sciences
Russian Federation

Valeriy M. Lebedev - Junior Research Fellow, Head of the Department of Neurology, Bechtereva Institute of the Human Brain of the Russian Academy of Sciences.

9, Akademik Pavlov St., St Petersburg, 197022


A. I. Nilov
Samara Regional Clinical Hospital named after V.D. Seredavin
Russian Federation

Aleksej I. Nilov - Neurologist, Head of the Consultative and Diagnostic Department of Neurology, Samara Regional Clinical Hospital named after V.D. Seredavin.

159, Tashkentskaya St., Samara, 443095


E. S. Novikova
Moscow Regional Research and Clinical Institute (“MONIKI”)
Russian Federation

Ekaterina S. Novikova - Neurologist of the Orphan Diseases Department of the Clinical Diagnostic Center, Junior Research Scientist, Moscow Regional Research and Clinical Institute (“MONIKI”).

61/2, Shchepkin St., Moscow 129110


E. V. Rybina
Lipetsk Regional Clinical Hospital
Russian Federation

Elena V. Rybina - Cand. Sci. (Med.), Associate Neurologist of the Neurology Department, Lipetsk Regional Clinical Hospital.

6a, Moskovskaya St., Lipetsk, 398042


A. А. Sokolova
Khanty-Mansiysk State Medical Academy; District Center of Multiple Sclerosis of the Khanty-Mansiysk Autonomous Okrug-Yugra District Clinical Hospital
Russian Federation

Azaliya А. Sokolova - Cand. Sci. (Med.), Associate Professor of the Department of Hospital Therapy, Khanty-Mansiysk State Medical Academy; Neurologist, Head of the District Center for Multiple Sclerosis, District Clinical Hospital.

40, Mira St., Khanty-Mansiysk AO – Yugra, Khanty-Mansiysk, 628011; 40, Kalinin St., Khanty-Mansiysk AO – Yugra, Khanty-Mansiysk, 628011


A. G. Streknev
Saratov City Clinical Hospital No. 9
Russian Federation

Andrey G. Streknev - Cand. Sci. (Med.), Neurologist, Head of the Saratov City Consultative and Methodological Center for Multiple Sclerosis, Saratov City Clinical Hospital No. 9.

43, Bolshaya Gornaya St., Saratov, 410031


M. V. Sutormin
Moscow Regional Research and Clinical Institute (“MONIKI”)
Russian Federation

Maxim V. Sutormin - Chief Neurologist of the Ministry of Health of the Russian Federation for the Central Federal District, Chief Neurologist of the Ministry of Health of the Moscow Region, Head of the Neurology and Rehabilitation Service, Moscow Regional Research and Clinical Institute (“MONIKI”).

61/2, Shchepkin St., Moscow, 129110


E. R. Tokareva
Order of the Red Banner of Labor Medical Institute named after S.I. Georgievsky of the Crimean Federal University named after V.I. Vernadsky; Sevastopol City Hospital No. 1 named after N.I. Pirogov
Russian Federation

Elena R. Tokareva - Cand. Sci. (Med.), Head of the Basic Department of Multidisciplinary Clinical Training, Multidisciplinary Clinical Training of the Order of the Red Banner of Labor of the Medical Institute named after S.I. Georgievsky, Crimean Federal University named after V.I. Vernadsky; Chief Specialist Neurologist of the Department of Health of the city of Sevastopol, Medical Worker, Head of the Department of Specialized Medical Care, branch No. 2 named after Dasha Sevastopolskaya, Sevastopol City Hospital No. 1 named after N.I. Pirogov.

4, Vernadskogo Ave., Simferopol, Republic of Crimea, 295007; 19, Admiral Oktyabrsky St., Sevastopol, 295007


N. V. Khachanova
Pirogov Russian National Research Medical University; Interdistrict Department of Multiple Sclerosis, City Clinical Hospital No. 24
Russian Federation

Natalia V. Khachanova - Cand. Sci. (Med.), Professor of the Department of Neurology, Neurosurgery and Medical Genetics, Pirogov Russian National Research Medical University; Neurologist of the Interdistrict Department of Multiple Sclerosis, City Clinical Hospital No. 24, Moscow Healthcare Department.

1, Ostrovityanov St., Moscow, 117513; 10, Pistcovaya St., Moscow, 127015


M. S. Cherepianskii
Komi Republican Clinical Hospital
Russian Federation

Maksim S. Cherepyansky - Deputy Chief Physician – Head of the Regional Vascular Center, Komi Republican Clinical Hospital.

114, Pushkin St., Syktyvkar, Republic of Komi, 167004


M. V. Shumilina
Pavlov First Saint Petersburg State Medical University; Saint-Petersburg City Center for Multiple Sclerosis and Other Autoimmune Diseases, City Clinical Hospital No. 31
Russian Federation

Maria V. Shumilina - Cand. Sci. (Med.), Head of the Оutpatient Department of the Saint-Petersburg City Center for Multiple Sclerosis and Other Autoimmune Diseases, City Clinical Hospital No. 31; Associate Professor of the Neurology Department, Pavlov First Saint Petersburg State Medical University.

3, Dynamo Ave., St Petersburg, 197110; 6–8, Lev Tolstoy St., St Petersburg, 197022


Yu. N. Yurchenko
Medical Center My Doctor
Russian Federation

Yulia N. Yurchenko - Cand. Sci. (Med.), Neurologist of the Office of Multiple Sclerosis, Medical Center My Doctor.

100, Krasnoarmeyskaya St., Bryansk, 241019


M. V. Davydovskaia
Interdistrict Department of Multiple Sclerosis, City Clinical Hospital No. 24; Clinical and Economic Analysis Scientific-Practical Center of the Moscow Region Healthcare Ministry
Russian Federation

Maria V. Davydovskaya - Dr. Sci. (Med.), Deputy Director of the Science of the Clinical and Economic Analysis Scientific-Practical Center of the Moscow Region Healthcare Ministry; Neurologist of the Interdistrict Department of Multiple Sclerosis, City Clinical Hospital No. 24, Moscow Healthcare Department.

4a, Karbyshev St., Krasnogorsk, 143403; 10, Pistcovaya St., Moscow 127015


References

1. Bruscolini A, Sacchetti M, La Cava M, Gharbiya M, Ralli M, Lambiase A et al. Diagnosis and management of neuromyelitis optica spectrum disorders – An update. Autoimmun Rev. 2018;17(3):195–200. https://doi.org/10.1016/j.autrev.2018.01.001.

2. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177–189. https://doi.org/10.1212/WNL.0000000000001729.

3. Ma X, Kermode AG, Hu X, Qiu W. NMOSD acute attack: Understanding, treatment and innovative treatment prospect. J Neuroimmunol. 2020;348:577387. https://doi.org/10.1016/j.jneuroim.2020.577387.

4. Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(22):2114–2124. https://doi.org/10.1056/NEJMoa1901747.

5. Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E, Shkrobot S et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disoder: a randomised, double-blind, multicentre, placebo-conroled phase 3 trial. Lancet Neurol. 2020;19(5):402–412. https://doi.org/10.1016/S1474-4422(20)30078-8.

6. Kleiter I, Traboulsee A, Palace J, Yamamura T, Fujihara K, Saiz A et al. Long-term Efficacy of satralizumab in AQP4-IgG–seropositive neuromyelitis optica spectrum disorder from SAkuraSky and SAkuraStar. Neurol Neuroimmunol Neuroinflamm. 2022;10(1):e200071. https://doi.org/10.1212/NXI.0000000000200071.

7. Yamamura T, Weinshenker B, Yeaman MR, De Seze J, Patti F, Lobo P et al. Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar. Mult Scler Relat Disord. 2022;66:104025. https://doi.org/10.1016/j.msard.2022.104025.

8. Bennett JL, Fujihara K, Saiz A, Traboulsee AL, Greenberg BM, Weinshenker BG et al. Long-Term Efficacy and safety of satralizumab in patients with neuromyelitis optica spectrum disorder from the SAkuraMoon open-label extension study. Neurol Neuroimmunol Neuroinflamm. 2025;12(6):e200494. https://doi.org/10.1212/NXI.0000000000200494.

9. Nakashima I, Nakahara J, Yasunaga H, Yamashita M, Nishijima N, Satomura A et al. Real-world management of patients with neuromyelitis optica spectrum disorder using satralizumab: results from a Japanese claims database. Mult Scler Relat Disord. 2024;84:105502. https://doi.org/10.1016/j.msard.2024.105502.

10. Yamamura T, Isobe N, Kawachi I, Nohara C, Miyazaki Y, Tomita M et al. Safety and Effectiveness of satralizumab in Japanese patients with neuromyelitis optica spectrum disorder: a 6-month interim analysis of post-marketing Surveillance. Neurol Ther. 2024;13(5):1361–1383. https://doi.org/10.1007/s40120-024-00640-7.

11. Abboud H, Steingo B, Vargas D, Patel J, Willis MA, Mao-Draayer Y et al. Satralizumab treatment in adults with aquaporin-4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorder in clinical practice. Mult Scler J Exp Transl Clin. 2025;11(4):20552173251386895. https://doi.org/10.1177/20552173251386895.

12. Yamamura T, Isobe N, Kawachi I, Nohara C, Miyazaki Y, Tomita M et al. Safety and Effectiveness of Satralizumab in Japanese Patients with Neuromyelitis Optica Spectrum Disorder: A 30-Month Interim Analysis of Post-marketing Surveillance. Neurol Ther. 2025;14(6):2429–2451. https://doi.org/10.1007/s40120-025-00799-7.

13. Fujihara K, Isobe N, Miyamoto K, Niino M, Nakahara J, Hattori S et al. Effectiveness of satralizumab in a real-world clinical setting in Japan: Interleukin-6 receptor inhibition in neuromyelitis optica spectrum disorder: A six-month interim analysis of a multicenter medical chart review. Mult Scler Relat Disord. 2025;98:106384. https://doi.org/10.1016/j.msard.2025.106384.

14. Kümpfel T, Giglhuber K, Aktas O, Ayzenberg I, Bellmann-Strobl J, Häußler V et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. J Neurol. 2024;271(1):141–176. https://doi.org/10.1007/s00415-023-11910-z.

15. Aljarallah S, AlThobaiti A, Abulaban A, AlDosari F, Alhasan S, Ali EN et al. Consensus recommendations for the diagnosis and management of neuromyelitis optica spectrum disorder: A Saudi expert panel review. Mult Scler Relat Disord. 2025;104:106847. https://doi.org/10.1016/j.msard.2025.106847.

16. Apóstolos-Pereira SLD, Damasceno A, Piccolo AC, Mendes MF, Brito ML, Alvarenga R et al. 2025 Brazilian guidelines for the management of neuromyelitis optica spectrum disorder in adults and children. Arq Neuropsiquiatr. 2025;83(11):s00451812471. https://doi.org/10.1055/s-0045-1812471.

17. Yamamura T, Araki M, Fujihara K, Okuno T, Misu T, Guo YC et al. Exploring steroid tapering in patients with neuromyelitis optica spectrum disorder treated with satralizumab in SAkuraSky: A case series. Mult Scler Relat Disord. 2022;61:103772. https://doi.org/10.1016/j.msard.2022.103772.

18. Li X, Wu W, Zeng Y, Wu W, Hou C, Zhu H et al. Satralizumab as an add-on treatment in refractory pediatric AQP4-antibody-positive neuromyelitis optica spectrum disorder: a case report. Front Immunol. 2023;14:1257955. https://doi.org/10.3389/fimmu.2023.1257955.

19. Pestchanker C, Diaconchuk M, Lopez P, Montaño MR, Romero W, Zalazar G, Contentti EC. Severe febrile neutropenia associated with satralizumab in an Argentinian neuromyelitis optica spectrum disorder patient. Mult Scler. 2023;29(1):150–153. https://doi.org/10.1177/13524585221137231.

20. Yoshida T, Watanabe O, Nomura M, Yoshimoto Y, Maki Y, Takashima H. Neuromyelitis optica spectrum disorder safely and successfully treated with satralizumab during pregnancy and breastfeeding: a case report. Front Neurol. 2023;14:1322412. https://doi.org/10.3389/fneur.2023.1322412.

21. Funakoshi K, Suzuki K. A safe change from eculizumab to satralizumab in a patient with neuromyelitis optica spectrum disorder. Neurol Sci. 2023;44(3):1097–1098. https://doi.org/10.1007/s10072-022-06495-w.

22. Abboud H, Steingo B, Vargas D, Patel J, Nealon N, Willis MA et al. Satralizumab treatment in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder after rituximab treatment: A case series. J Neuroimmunol. 2025;403:578585. https://doi.org/10.1016/j.jneuroim.2025.578585.

23. Abboud H, Subei A, Sengul B, Shin RK, Goulette P, Walch R et al. Switch from eculizumab to satralizumab in aquaporin 4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorder: a case series report. Front Immunol. 2025;15:1526563. https://doi.org/10.3389/fimmu.2024.1526563.

24. Krasnov VS, Bakhtiyarova KZ, Evdoshenko EP, Korobko DS, Simaniv TO, Totolyan NA et al. Consensus opinion on the management of patients with neuromyelitis optica spectrum diseases: issues of terminology and therapy. Neurology, Neuropsychiatry, Psychosomatics. 2022;14(6):139–148. (In Russ.) https://doi.org/10.14412/2074-2711-2022-6-139-148.

25. Krasnov VS, Vlasov YaV, Evdoshenko EP, Korobko DS, Matson MD, Nilov AI et al. Neuromyelitis optica spectrum disorders, terminology and therapeutic issues: amended consensus opinion. Neurology, Neuropsychiatry, Psychosomatics. 2024;16(6):134–143. (In Russ.) https://doi.org/10.14412/2074-2711-2024-6-134-143.

26. Prakhova LN, Krasnov VS, Kasatkin DS, Korobko DS. Local experience of IL-6 pathway inhibition with satralizumab for patients with neuromyelitis optica spectrum disorder. Differential diagnosis of multiple sclerosis in children. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2022;122(7-2):68–72. (In Russ.) https://doi.org/10.17116/jnevro202212207268.

27. Bronina NV, Bykova OV, Bronin GO, Kessel AE, Seregin GZ, Kirgizov KI et al. High-dose immunosuppressive therapy followed by haematopoietic stem cell transplantation as a method for the treatment of refractory forms of neuromyelitis optica spectrum disorder in children. Neurology, Neuropsychiatry, Psychosomatics.2024;16(2):74–82. (In Russ.) https://doi.org/10.14412/2074-2711-2024-2S-74-82.

28. Барабанова МА, Головко ЕН, Кривомлина ЕВ. Опыт использования сатрализумаба у пациентов с заболеваниями спектра оптиконевромиелита в Краснодарском крае. В: Международный конгресс: «Рассеянный склероз и другие нейроиммунологические мероприятия»: материалы конференции. Санкт-Петербург, 23–26 мая 2024 г. СПб.: Медицинская ассоциация врачей и центров рассеянного склероза и других нейроиммунологических заболеваний; 2024. Режим доступа: https://www.mapcms.ru/upload/congress/tezises_2024.pdf.

29. Токарева ЕР. Влияние сатрализумаба на качество жизни пациентов с заболеваниями спектра оптиконевромиелита (клинический опыт применения в г. Севастополь). В: Международный конгресс: «Рассеянный склероз и другие нейроиммунологические мероприятия»: материалы конференции. Санкт-Петербург, 23–26 мая 2024 г. СПб.: Медицинская ассоциация врачей и центров рассеянного склероза и других нейроиммунологических заболеваний; 2024. С. 7–8. Режим доступа: https://www.mapcms.ru/upload/congress/tezises_2024.pdf.

30. Novikova ES, Kotov SV, Kotov AS. The use of satralizumab in patients with DM (experience of the Moscow region). Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2025;125(7-2):121. (In Russ.) https://doi.org/10.17116/jnevro2025125072101.

31. Akaishi T, Nakashima I, Takahashi T, Abe M, Ishii T, Aoki M. Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence. Neurol Neuroimmunol Neuroinflamm. 2019;7(1):e640. https://doi.org/10.1212/NXI.0000000000000640.

32. Wang C, Liu J, Gao X, Shen Y, Pan J, Yang S et al. Effectiveness and safety of glucocorticoids bridging rituximab in neuromyelitis spectrum disorder. Mult Scler Relat Disord. 2025;95:106314. https://doi.org/10.1016/j.msard.2025.106314.

33. Greenberg BM, Fujihara K, Weinshenker B, Patti F, Kleiter I, Bennett JL et al. Analysis of infection rates in neuromyelitis optica spectrum disorder: Comparing satralizumab treatment in SAkuraMoon, post-marketing, and US-based health claims data. Mult Scler Relat Disord. 2025;99:106444. https://doi.org/10.1016/j.msard.2025.106444.

34. Zou S, Ouyang M, Cheng Q, Shi X, Zhao Y, Sun M. IL-6R Inhibitors and Gastrointestinal Perforations: A Pharmacovigilance Study and a Predicting Nomogram. Biomedicines. 2024;12(12):2860. https://doi.org/10.3390/biomedicines12122860.

35. Akatani R, Chihara N, Hara A, Tsuji A, Koto S, Kobayashi K et al. Interleukin-6 signaling blockade induces regulatory plasmablasts in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2024;11(4):e200266. https://doi.org/10.1212/NXI.0000000000200266.

36. Lehmann-Horn K, Schleich E, Hertzenberg D, Hapfelmeier A, Kümpfel T, von Bubnoff N et al. Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders. J Neuroinflammation. 2011;8:146. https://doi.org/10.1186/1742-2094-8-146.

37. Yao Y, Yang X, Zhou Y, Xie H, Duan R, Jing L et al. Comparative analysis of clinical and imaging data of first-attack neuromyelitis optica spectrum disorders with and without connective tissue disease. Front Neurol. 2022;13:969762. https://doi.org/10.3389/fneur.2022.969762.

38. Paul F, Marignier R, Palace J, Arrambide G, Asgari N, Bennett JL et al. International Delphi consensus on the management of AQP4-IgG+ NMOSD: recommendations for eculizumab, inebilizumab, and satralizumab. Neurol Neuroimmunol Neuroinflamm. 2023;10(4):e200124. https://doi.org/10.1212/NXI.0000000000200124.

39. Lin J, Xue B, Li J, Xie D, Weng Y, Zhang X et al. The relationship between neuromyelitis optica spectrum disorder and autoimmune diseases. Front Immunol. 2024;15:1406409. https://doi.org/10.3389/fimmu.2024.1406409.

40. Traboulsee A, Yeaman MR, Weinshenker BG, Palace J, Kleiter I, Kou X et al. Satralizumab in patients with neuromyelitis optica spectrum disorder (NMOSD) and concomitant autoimmune disease (CAID) [Presentation]. In: 7th Congress of the European Academy of Neurology (EAN), Virtual congress, 19–22 June 2021. Available at: https://www.cuba.dialogoroche.com/content/dam/roche-dialogo/global-assets/downloadable-assets/neurology/roche-ean-2021/presentaciones/satralizumab-in-patients-with-neuromyelitis-optica-spectrum-disorder-and-concomitant-autoimmune-disease.pdf.

41. Abboud H, Steingo B, Vargas D, Patel J, Nealon N, Willis MA et al. Satralizumab treatment in adult patients with AQP4-IgG–seropositive neuromyelitis optica spectrum disorder switching from other therapies: a case series [Presentation]. In: Eighth Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum. San Diego, CA, 23–25 February 2023. Available at: https://www.cuba.dialogoroche.com/content/dam/roche-dialogo/global-assets/downloadable-assets/congresos-y-eventos/neurology/actrims-forum-2023/05-actrims-forum-2023-poster-abboud-satralizumab-treatment-in-adult-patients.pdf.


Review

For citations:

Krasnov VS, Abramova MP, Bakalova MA, Bezvodinskikh AI, Bembeeva RT, Gasanova ZS, Evdoshenko EP, Zhukovskaya NV, Zaplakhova OV, Ivanova SP, Ignateva OS, Kasatkin DS, Korobko DS, Krivomlina EV, Kushtynova VE, Lebedev VM, Nilov AI, Novikova ES, Rybina EV, Sokolova AА, Streknev AG, Sutormin MV, Tokareva ER, Khachanova NV, Cherepianskii MS, Shumilina MV, Yurchenko YN, Davydovskaia MV. Experience of satralizumab administration in patients with neuromyelitis optica spectrum disorder in the Russian Federation. Meditsinskiy sovet = Medical Council. 2026;(3):114-129. (In Russ.) https://doi.org/10.21518/ms2026-042

Views: 598

JATS XML


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)

71, Bldg. 10, Bakuninskaya St., Moscow, 105082, Russia
Phone. +7 (495) 780-34-25
Fax +7 (495) 780-3425
e-mail: panarina@remedium.ru 

Processing of personal data
supported by NEICON (Elpub lab)